Patents Assigned to Critical Care Diagnostics, Inc.
-
Patent number: 10203339Abstract: This invention relates to methods for the detection of cardiovascular disease, e.g., acute coronary syndrome, heart failure and/or pulmonary embolism, in high body mass index (BMI) individuals, e.g., with a BMI of 25-29, or 30 or above, and those with impaired renal function.Type: GrantFiled: May 1, 2007Date of Patent: February 12, 2019Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Sven Jacobson
-
Publication number: 20190041403Abstract: Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease.Type: ApplicationFiled: August 13, 2018Publication date: February 7, 2019Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Sven Jacobson
-
Publication number: 20180292415Abstract: Provided are methods for evaluating the risk of an adverse clinical outcome in a subject, deciding whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis), or to initiate or terminate treatment, selecting a subject for participation in a clinical study, and selecting a therapeutic treatment for a subject that include determining a level of ST2 in a biological sample from the subject and determining a level of galectin-3 in a biological sample from the subject. Kits are also provided that contain an antibody that specifically binds to ST2, an antibody that specifically binds to galectin-3, and instructions for using the kit to evaluate the risk of an adverse clinical outcome in a subject, to decide whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis) or to initiate or terminate treatment, to select a subject for participation in a clinical study, and/or to select treatment for a subject.Type: ApplicationFiled: November 1, 2017Publication date: October 11, 2018Applicant: Critical Care Diagnostics, Inc.Inventor: James V. Snider
-
Patent number: 10079073Abstract: The technology described in this document can be embodied in a test strip for use in measuring a level of an ST2 cardiac biomarker in a blood plasma sample. The test strip includes a base, and a plurality of conjugates, wherein each conjugate includes a reporter group bound to a first antibody that binds to ST2. A conjugate pad disposed along a length of the base and is configured to hold the plurality of conjugates that bind with ST2 to produce conjugate-ST2 complexes. The conjugate pad is further configured to receive the blood plasma sample. The test strip also includes a plurality of second and third antibodies that bind to ST2, and the conjugate-ST2 complexes, respectively. The plurality of second antibodies are bound to a membrane in a test location and the plurality of third antibodies are bound to the membrane in a control location.Type: GrantFiled: December 11, 2014Date of Patent: September 18, 2018Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Jillian Elizabeth Bender, Shrin P. Kuo, Roy A. Chung
-
Patent number: 10067146Abstract: Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease.Type: GrantFiled: January 19, 2017Date of Patent: September 4, 2018Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Sven Jacobson
-
Publication number: 20180233229Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.Type: ApplicationFiled: April 12, 2018Publication date: August 16, 2018Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Eugene R. Heyman
-
Patent number: 10041957Abstract: Methods using biomarkers, e.g., serum levels of ST2, to predict risk of developing hypertension, as well as methods for treating subjects to reduce the risk of developing hypertension and methods for selecting and/or stratifying subjects for clinical trials of treatments to reduce the risk of hypertension.Type: GrantFiled: December 19, 2016Date of Patent: August 7, 2018Assignee: Critical Care Diagnostics, Inc.Inventor: James V. Snider
-
Patent number: 9965593Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.Type: GrantFiled: April 3, 2014Date of Patent: May 8, 2018Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Eugene R. Heyman
-
Patent number: 9886553Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.Type: GrantFiled: March 6, 2013Date of Patent: February 6, 2018Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Eugene R. Heyman
-
Publication number: 20180018442Abstract: Provided are methods, algorithms, nomograms, and computer/software systems that can be used to accurately determine the risk of developing heart failure within a specific time period in a subject not diagnosed or presenting with heart failure. Also provided are methods, algorithms, nomograms, computer/software systems for selecting a treatment for a subject and determining the efficacy of a treatment for reducing the risk of heart failure in a subject.Type: ApplicationFiled: October 4, 2017Publication date: January 18, 2018Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien
-
Patent number: 9823257Abstract: Provided are methods for evaluating the risk of an adverse clinical outcome in a subject, deciding whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis), or to initiate or terminate treatment, selecting a subject for participation in a clinical study, and selecting a therapeutic treatment for a subject that include determining a level of ST2 in a biological sample from the subject and determining a level of galectin-3 in a biological sample from the subject. Kits are also provided that contain an antibody that specifically binds to ST2, an antibody that specifically binds to galectin-3, and instructions for using the kit to evaluate the risk of an adverse clinical outcome in a subject, to decide whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis) or to initiate or terminate treatment, to select a subject for participation in a clinical study, and/or to select treatment for a subject.Type: GrantFiled: January 12, 2016Date of Patent: November 21, 2017Assignee: Critical Care Diagnostics, Inc.Inventor: James V. Snider
-
Publication number: 20170219610Abstract: Methods using biomarkers, e.g., serum levels of ST2, to predict risk of developing hypertension, as well as methods for treating subjects to reduce the risk of developing hypertension and methods for selecting and/or stratifying subjects for clinical trials of treatments to reduce the risk of hypertension.Type: ApplicationFiled: December 19, 2016Publication date: August 3, 2017Applicant: Critical Care Diagnostics, Inc.Inventor: James V. Snider
-
Publication number: 20170169179Abstract: Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.Type: ApplicationFiled: December 20, 2016Publication date: June 15, 2017Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien, Sven Jacobson
-
Publication number: 20170146552Abstract: Provided herein are methods that include (i) determining a level of soluble ST2 in a biological sample from a subject, (i) comparing the level of soluble ST2 in the biological sample to a reference level of soluble ST2 (e.g., a level of soluble ST2 in the subject at an earlier time point), and (iii) selecting, implanting, replacing, or reprogramming an implanted cardiac device, e.g., an ICD, CRT, or CRT-D device, for a subject having an elevated level of soluble ST2 in the biological sample compared to the reference level of soluble ST2, or selecting a subject for participation in, or stratifying a subject participating in, a clinical study of a treatment for reducing the risk of a ventricular tachyarrhythmia (VTA) event. Also provided are methods for evaluating the risk of a VTA event in a subject. Also provided are kits for performing any of these methods.Type: ApplicationFiled: December 6, 2016Publication date: May 25, 2017Applicants: Critical Care Diagnostics, Inc., Cardiac Pacemakers, Inc.Inventors: James V. Snider, Timothy Edward Meyer, Craig Michael Stolen, Robert W. Gerwien
-
Publication number: 20170131294Abstract: Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease.Type: ApplicationFiled: January 19, 2017Publication date: May 11, 2017Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Sven Jacobson
-
Publication number: 20170122942Abstract: Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or avoid exercise therapy, determining whether a subject having a cardiovascular disease should continue, discontinue, or avoid exercise therapy, reducing the risk of an adverse outcome (e.g., death) in a subject having a cardiovascular disease, and predicting the efficacy of exercise therapy in a subject having a cardiovascular disease. These methods include determining a level of soluble ST2 in a subject.Type: ApplicationFiled: January 18, 2017Publication date: May 4, 2017Applicant: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien
-
Patent number: 9568481Abstract: Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease.Type: GrantFiled: October 26, 2011Date of Patent: February 14, 2017Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Sven Jacobson
-
Patent number: 9551708Abstract: Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or avoid exercise therapy, determining whether a subject having a cardiovascular disease should continue, discontinue, or avoid exercise therapy, reducing the risk of an adverse outcome (e.g., death) in a subject having a cardiovascular disease, and predicting the efficacy of exercise therapy in a subject having a cardiovascular disease. These methods include determining a level of soluble ST2 in a subject.Type: GrantFiled: June 9, 2014Date of Patent: January 24, 2017Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, Robert W. Gerwien
-
Patent number: D800332Type: GrantFiled: September 23, 2014Date of Patent: October 17, 2017Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, David Geliebter
-
Patent number: D800333Type: GrantFiled: September 23, 2014Date of Patent: October 17, 2017Assignee: Critical Care Diagnostics, Inc.Inventors: James V. Snider, David Geliebter